Yes, complement proteins can be therapeutic targets. Inhibitors of the complement system, such as eculizumab, are used in the treatment of diseases like paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. These therapies aim to modulate the complement system to prevent unwanted tissue damage.
